Viral Gastroenteritis Clinical Trials

Find Viral Gastroenteritis Clinical Trials Near You

Treat-to-Target and Disease Modification in Inflammatory Bowel Disease: A Worldwide Routine Practice Study

Status: Recruiting
Location: See all (4) locations...
Study Type: Observational
SUMMARY

Inflammatory Bowel Disease (IBD), encompassing Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic, relapsing, and often disabling condition characterized by inflammation of the gastrointestinal tract. A treat-to-target strategy (T2T) is recommended by international guidelines to optimize long-term outcomes in IBD. The purpose of this study is to describe the real-life implementation of T2T in IBD worldwide and the association between using a T2T strategy and disease outcomes. This is a multi-country, observational, retrospective (non-interventional) study with a cross-sectional component based upon a sample of adult participants with IBD. All objectives will be assessed for IBD and then for CD/UC separately. Primary and secondary objectives will be assessed for the overall population over the 24 months study period. As this is an observational study, enrolled participants will be managed and followed up according to the standard practice. Retrospective chart review over the 24-months from date of inclusion will allow us to collect the variables of interest by using an e-CRF. There will be no additional burden for participants in this trial. Study visits will not be required as this is a retrospective chart review.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Healthy Volunteers: f
View:

• Adult male and female participants (\>= 18 years old) at the inclusion date who present within the usual course of care

• Participants able to provide voluntary informed consent prior to any study data collection

• Participant diagnosed with Crohn's Disease (CD) or Ulcerative Colitis (UC) for at least 24 months at the inclusion date

• With \>= 24 months of available medical records from the inclusion date

Locations
Other Locations
China
Chongqing General Hospital /ID# 282777
RECRUITING
Chongqing
France
CHU Amiens-Picardie Site Sud /ID# 280263
NOT_YET_RECRUITING
Amiens
Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire Carémeau /ID# 282775
NOT_YET_RECRUITING
Nîmes
Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois /ID# 280265
NOT_YET_RECRUITING
Vandœuvre-lès-nancy
Contact Information
Primary
Colla Cunneen
colla.cunneen@abbvie.com
708-650-3696
Time Frame
Start Date: 2026-02-09
Estimated Completion Date: 2026-09
Participants
Target number of participants: 2000
Treatments
Adults with Inflammatory Bowel Disease
Participants will be managed and followed according to the standard practice.
Sponsors
Leads: AbbVie

This content was sourced from clinicaltrials.gov